Butterfly Network, Inc. BFLY

Butterfly Network, Inc., anteriormente Longview Acquisition Corp., es una empresa de salud digital. La empresa se dedica principalmente a ofrecer un sistema de imágenes médicas, Butterfly iQ. El Butterfly iQ es un sistema de ultrasonido portátil de sonda única de cuerpo entero, que utiliza tecnología de semiconductores. Los productos de la empresa están impulsados por su tecnología Ultrasound-on-Chip, que es un transductor de ultrasonido que puede realizar imágenes de todo el cuerpo. Su sistema de ultrasonido está compuesto tanto por soluciones de hardware como de software diseñadas para hacer que la imagen de ultrasonido sea accesible para todos los profesionales de la salud, incluidos enfermeras, parteras y, en última instancia, pacientes directamente. Butterfly iQ está disponible comercialmente en aproximadamente 20 países, incluidos Estados Unidos, Canadá, Australia, Nueva Zelanda y Europa. La empresa también tiene un sitio web de comercio electrónico a través del cual vende su Butterfly iQ+ a profesionales de la salud. Su Butterfly iQ+ se conecta a un teléfono inteligente o tableta para realizar exploraciones de ultrasonido.

• GlobeNewswire Inc. 16 sept

  Ultrasound AI Market Size to Surge to USD 22.03 Billion by 2035 at a CAGR of 26.62% – SNS Insider

  The global Ultrasound AI market is projected to grow from USD 2.09 billion in 2025 to USD 22.03 billion by 2035, with a CAGR of 26.62%. Growth is driven by deep learning advancements, point-of-care imaging adoption, and sonographer shortages. North America leads with 45.54% market share, while Asia-Pacific shows the fastest growth at 28.57% CAGR. Hardware dominates at 48% market share, with software as the fastest-growing segment.

  

• The Motley Fool 21 ago

  Butterfly Network Director Phanstiel Buys $1.0 Million in Stock. Is This a Sign Investors Should Also Buy?

  Butterfly Network director Louise S. Phanstiel purchased 115,200 shares worth $1.0 million at $8.68 per share, increasing her total beneficial ownership to 691,413 shares (0.26% of the company). The insider purchase is viewed as a bullish signal, particularly given Phanstiel's healthcare expertise. Analysts project 19% revenue growth for the current fiscal year and expect the company to double its 2026 revenue by 2028 while narrowing net losses.

  

• The Motley Fool 27 jul

  Butterfly Network Founder Rothberg Sells Another 660,000 Shares. Should Investors Worry?

  Butterfly Network founder Jonathan Rothberg sold approximately 660,000 shares (~$4.3 million) on July 22, 2026, under a pre-scheduled Rule 10b5-1 trading plan for estate planning purposes. While the sale was pre-planned, analysts note it's concerning timing given the stock's 250% surge over the past year and multiple recent insider sales. Despite positive analyst outlooks for 2026 revenue growth of 22%, investors are advised to reconsider their investment thesis given the founder's share liquidation near five-year highs.

  

• The Motley Fool 22 jul

  Butterfly Network Founder Jonathan Rothberg Sells Nearly $21 Million in Shares. What Does This Mean for Investors?

  Butterfly Network founder Jonathan Rothberg sold approximately 3.1 million Class B shares worth $20.7 million at $6.64 per share through a pre-planned Rule 10b5-1 trading plan established for estate planning purposes. While the sale was scheduled in advance, analysts note it could signal reduced confidence given the stock's 263% rally over 12 months. Rothberg retains 19.7 million shares indirectly through various trusts and entities.

  

• The Motley Fool 5 jul

  Butterfly Network Insider Sheds 399K Shares — This Stock May Be Ready to Take Flight

  Butterfly Network's Chief Business Officer Steve Cashman sold 399,461 shares (19.68% of his direct holdings) for approximately $1.9 million in June 2026. The sale marks his largest single open-market transaction to date. While the stock has surged 291.8% over the past year, the analyst suggests the recent rally may have already priced in future growth, particularly from a new Midjourney licensing deal worth $10 million annually plus milestone payments. The core ultrasound business shows solid but unspectacular growth (19-25%), creating concentration risk around the single licensing relationship.